Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | PQR309 |
| Trade Name | |
| Synonyms | PQR 309|PQR-309|Bimiralisib |
| Drug Descriptions |
PQR309 (Bimiralisib) is a dual pan-PI3K and mTORC1/2 inhibitor, which blocks PI3K/mTOR signaling, potentially resulting in inhibition of tumor growth (PMID: 29066507). |
| DrugClasses | mTOR Inhibitor 51 PI3K Inhibitor (Pan) 42 |
| CAS Registry Number | 1225037-39-7 |
| NCIT ID | C111898 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Ibrutinib + PQR309 | Ibrutinib PQR309 | 0 | 0 |
| Panobinostat + PQR309 | PQR309 Panobinostat | 0 | 0 |
| PQR309 | PQR309 | 0 | 4 |
| PQR309 + Rituximab | PQR309 Rituximab | 0 | 0 |
| PQR309 + Venetoclax | PQR309 Venetoclax | 0 | 0 |